Benzinga's Top Upgrades, Downgrades For December 31, 2018

Top Upgrades

• B. Riley FBR upgraded Deciphera Pharmaceuticals Inc DCPH from Neutral to Buy. Deciphera Pharmaceuticals shares fell 0.63 percent to close at $20.59 on Friday.
• Northland Capital upgraded II-VI, Inc. IIVI from Market Perform to Outperform. II-VI shares closed at $31.82 on Friday.

Top Initiations

• Analysts at B. Riley FBR resumed coverage on Uniqure NV QURE with a Buy rating. The price target for Uniqure is set to $72. Uniqure closed at $26.94 on Friday.
• WBB Securities initiated coverage on RedHill Biopharma Ltd. RDHL with a Speculative Buy rating. RedHill Biopharma closed at $5.36 on Friday. 
• B. Riley FBR resumed coverage on Tocagen Inc TOCA with a Buy rating. The price target for Tocagen is set to $22. Tocagen shares closed at $7.95 on Friday.
• B. Riley FBR resumed coverage on Iovance Biotherapeutics Inc IOVA with a Buy rating. The price target for Iovance Biotherapeutics is set to $24. Iovance Biotherapeutics shares closed at $8.99 on Friday.
• B. Riley FBR resumed coverage on Miragen Therapeutics Inc MGEN with a Buy rating. The price target for Miragen Therapeutics is set to $18.5. Miragen Therapeutics shares closed at $2.68 on Friday.